SEC Form 4
InMed Pharmaceuticals Inc. Common Shares (INM) insider trading
In the 12 months to Oct 26, 2026, 5 INM insiders reported open-market purchases of $1.4M across 17 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $1.4M
- 17 filings
Who traded INM, and when
- Purchase
INM daily close from Oct 27, 2025 to Oct 26, 2026, between $0.62 and $2.04, last $1.56. 0 sale and 17 purchase filings by 5 insiders, marked at their filing dates. Daniel Schneeberger, 10% owner: bought $926.9K across 7 filings, first filed May 21, 2026, last Oct 20, 2026. Vivo Opportunity Cayman, LLC, 10% owner: bought $166.2K across 3 filings, first filed Jun 10, 2026, last Jul 16, 2026. Vivo Opportunity, LLC, 10% owner: bought $162.6K across 3 filings, first filed Jun 10, 2026, last Jul 16, 2026. Vivo Opportunity Cayman Fund, L.P., 10% owner: bought $78.4K across 2 filings, first filed Jun 10, 2026, last Jul 16, 2026. Vivo Opportunity Fund Holdings, L.P., 10% owner: bought $26.4K across 2 filings, first filed Jun 10, 2026, last Jul 2, 2026.
Largest mark · tap a row for others
Daniel Schneeberger · 10% owner
Purchase $721,548
468,551 shares at $1.54 avg
Filed May 21, 2026 · traded May 19
Close on filing date $1.73
Daniel Schneeberger · 10% owner
10% owner
$926.9K boughtVivo Opportunity Cayman, LLC · 10% owner
10% owner
$166.2K boughtVivo Opportunity, LLC · 10% owner
10% owner
$162.6K boughtVivo Opportunity Cayman Fund, L.P. · 10% owner
10% owner
$78.4K boughtVivo Opportunity Fund Holdings, L.P. · 10% owner
10% owner
$26.4K boughtOpen-market trades
17 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Daniel Schneeberger | 10% owner | — | $926.9K | 7 | — | |
| Vivo Opportunity Cayman, LLC | 10% owner | — | $166.2K | 3 | — | |
| Vivo Opportunity, LLC | 10% owner | — | $162.6K | 3 | — | |
| Vivo Opportunity Cayman Fund, L.P. | 10% owner | — | $78.4K | 2 | — | |
| Vivo Opportunity Fund Holdings, L.P. | 10% owner | — | $26.4K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Daniel Schneeberger 10% owner | Purchase | 1,087 | $1.32 | $1.4K | 956,580 | |
traded | Daniel Schneeberger 10% owner | Purchase | 9,569 | $1.33 | $12.7K | 955,493 | |
traded | Daniel Schneeberger 10% owner | Purchase | 10,903 | $1.33 | $14.5K | 945,924 | |
traded | Daniel Schneeberger 10% owner | Purchase | 42,920 | $1.33 | $57.1K | 935,021 | |
traded | Daniel Schneeberger 10% owner | Purchase | 91,101 | $1.30 | $118.1K | 892,101 | |
traded | Daniel Schneeberger 10% owner | Purchase | 1,000 | $1.56 | $1.6K | 801,000 | |
traded | Vivo Opportunity, LLC 10% owner | Purchase | 1,410 | $1.55 | $2.2K | Multiple accounts | |
traded | Vivo Opportunity Cayman Fund, L.P. 10% owner | Purchase | 14,254 | $1.55 | $22.1K | Multiple accounts | |
traded | Vivo Opportunity Cayman, LLC 10% owner | Purchase | 4,882 | $1.55 | $7.6K | 729,277 | |
traded | Vivo Opportunity, LLC 10% owner | Purchase | 2,060 | $1.55 | $3.2K | Multiple accounts | |
traded | Vivo Opportunity Fund Holdings, L.P. 10% owner | Purchase | 545 | $1.54 | $839 | 718,989 | |
traded | Vivo Opportunity Cayman, LLC 10% owner | Purchase | 3,946 | $1.55 | $6.1K | 722,935 | |
traded | Vivo Opportunity Cayman, LLC 10% owner | Purchase | 94,908 | $1.61 | $152.5K | Multiple accounts | |
traded | Vivo Opportunity Fund Holdings, L.P. 10% owner | Purchase | 16,537 | $1.55 | $25.6K | Multiple accounts | |
traded | Vivo Opportunity Cayman Fund, L.P. 10% owner | Purchase | 36,047 | $1.56 | $56.3K | Multiple accounts | |
traded | Vivo Opportunity, LLC 10% owner | Purchase | 101,735 | $1.54 | $157.2K | Multiple accounts | |
traded | Daniel Schneeberger 10% owner | Purchase | 468,551 | $1.54 | $721.5K | 400,000 |
GET /stocks/filings/vX/form-4?tickers=INM&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"INM"
],
"issuer_cik": "0001728328",
"owner_cik": "0001940272",
"accession_number": "0001940272-26-000026",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-16",
"issuer_name": "InMed Pharmaceuticals Inc.",
"issuer_trading_symbol": "INM",
"owner_name": "ADAR1 Capital Management, LLC",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-16",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1,
"transaction_price_per_share": 1.32,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 955494,
"transaction_value": 1.32,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnote",
"footnotes": [
{
"id": "F1",
"description": "The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."
},
{
"id": "F2",
"description": "For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."
}
]
},
{
"tickers": [
"INM"
],
"issuer_cik": "0001728328",
"owner_cik": "0001861120",
"accession_number": "0001940272-26-000026",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-16",
"issuer_name": "InMed Pharmaceuticals Inc.",
"issuer_trading_symbol": "INM",
"owner_name": "Schneeberger Daniel",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-16",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1,
"transaction_price_per_share": 1.32,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 955494,
"transaction_value": 1.32,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnote",
"footnotes": [
{
"id": "F1",
"description": "The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."
},
{
"id": "F2",
"description": "For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has InMed Pharmaceuticals Inc. Common Shares' CEO sold stock?
No. Eric A. Adams (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is INM’s insider data?
These are INM Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track INM insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for INM every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.